This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Reyes-del Valle, J.
Right arrow Articles by Cattaneo, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reyes-del Valle, J.
Right arrow Articles by Cattaneo, R.

 Previous Article  |  Next Article 

Journal of Virology, September 2009, p. 9013-9017, Vol. 83, No. 17
0022-538X/09/$08.00+0     doi:10.1128/JVI.00906-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Protective Anti-Hepatitis B Virus Responses in Rhesus Monkeys Primed with a Vectored Measles Virus and Boosted with a Single Dose of Hepatitis B Surface Antigen{triangledown}

Jorge Reyes-del Valle,1 Gregory Hodge,2 Michael B. McChesney,2 and Roberto Cattaneo1*

Department of Molecular Medicine and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, Rochester, Minnesota 55905,1 California National Primate Research Center and Department of Pathology and Laboratory Medicine, School of Medicine, University of California—Davis, Davis, California 956162

Received 6 May 2009/ Accepted 8 June 2009

The widely used hepatitis B virus (HBV) vaccine is based on three doses of hepatitis B surface antigen (HBsAg) protein. We previously showed that vectored measles viruses (MV) expressing HBsAg retain measles vaccine function in monkeys but do not induce a protective anti-HBs response in all animals. We show here that a single dose of HBsAg protein following a three-dose vaccination regimen with an optimized HBsAg-expressing MV elicits protective anti-HBs responses in all four vaccinated Rhesus monkeys. Vaccination strategies coupling the effective, long-term immunity elicited by the high-coverage MV vaccine to prophylactic HBV immunity are discussed.

* Corresponding author. Mailing address: Department of Molecular Medicine and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, Guggenheim 18-42B, 200 First Street SW, Rochester, MN 55905. Phone: (507) 284-0171. Fax: (507) 262-2122. E-mail: Cattaneo.Roberto{at}mayo.edu

{triangledown} Published ahead of print on 17 June 2009.

Journal of Virology, September 2009, p. 9013-9017, Vol. 83, No. 17
0022-538X/09/$08.00+0     doi:10.1128/JVI.00906-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»